Prediction: It's Time to Buy Philip Morris International Stock on the Pullback

Philip Morris International (PM) reported robust Q3 results, with organic revenue up 5.9% to $10.8 billion and adjusted EPS climbing 17.3% to $2.24, largely driven by strong performance in its smoke-free portfolio, including Zyn nicotine pouches (U.S. shipments +37%) and heated tobacco units (+15.5%). Despite maintaining full-year organic revenue guidance and slightly raising adjusted EPS forecasts, the stock experienced a pullback due to investor scrutiny over increased promotional spending for Zyn. This dip is presented as a buying opportunity, given the sustained growth of its smoke-free segments, the potential for future expansion with Iqos ILUMA, and an attractive valuation characterized by a forward P/E under 18 and a ~4% dividend yield.

Analysis

Philip Morris International (PM) reported robust third-quarter results, with organic revenue increasing 5.9% year-over-year to $10.8 billion and adjusted EPS climbing 17.3% to $2.24. This strong performance was primarily driven by its smoke-free portfolio, notably Zyn nicotine pouches, which saw U.S. shipments surge 37% and global shipments rise 36%. Heated tobacco units (HTUs), including Iqos, also contributed significantly with a 15.5% volume jump to 40.8 billion units. Traditional cigarette volumes, however, declined by 3.2%.

Despite maintaining full-year organic revenue guidance and slightly raising adjusted EPS forecasts from $7.33-$7.46 to $7.46-$7.56, PM's stock experienced a pullback. This investor apprehension stemmed from increased promotional spending for Zyn, including a $100 million investment in Q3 for free product offers. Management, however, noted these promotions targeted smokers and vapers, accounting for a single-digit percentage of shipments, and were a strategic move following prior supply constraints.

The current valuation presents an attractive entry point, with PM trading at a forward P/E ratio of under 18 based on 2026 analyst consensus and a PEG ratio below 0.7, indicating potential undervaluation. The company also offers a forward dividend yield just under 4%. Future growth is anticipated from continued Zyn and Iqos expansion, with the potential for Iqos ILUMA's U.S. FDA approval to serve as another significant catalyst.

Key Decisions for Investors

• Investors should consider the recent stock pullback as a potential buying opportunity, given PM's strong smoke-free growth drivers and attractive valuation metrics like a sub-18 forward P/E and ~4% dividend yield.
• Monitor the effectiveness of Zyn's promotional strategies and potential for sustained market share gains, alongside the progress of Iqos ILUMA's FDA approval for U.S. market expansion.
• Evaluate PM's defensive growth profile within the consumer staples sector, balancing continued traditional cigarette volume declines against robust smoke-free segment expansion.